&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;strong&gt;APRETUDE for Different Communities&lt;/strong&gt;&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Women&lt;/strong&gt; APRETUDE caters to women&amp;rsquo;s unique health needs, providing a reliable, hassle-free HIV prevention option.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Men&lt;/strong&gt; For men, APRETUDE eliminates the daily pill burden, offering consistent protection without daily reminders.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Gay Men&lt;/strong&gt; APRETUDE benefits gay men by improving adherence and offering a discreet prevention method.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Transgender Individuals&lt;/strong&gt; Transgender individuals face unique healthcare challenges. APRETUDE supports transgender health by offering an effective, convenient HIV prevention option.&lt;/p&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h2&gt;&lt;strong&gt;Efficacy of Apretude for all populations&lt;/strong&gt;&lt;/h2&gt;
&lt;hr /&gt;
&lt;p class=&quot;&quot;&gt;Based on the research study&lt;/p&gt;
&lt;table style=&quot;border-collapse: collapse; width: 100%; height: 90px;&quot; border=&quot;1&quot;&gt;
&lt;tbody&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;&amp;nbsp;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot; colspan=&quot;5&quot;&gt;Injectable PrEP Apretude Efficacy in Different Populations&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;&lt;strong&gt;Route or Sex&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;Straight Men&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;Straight Women&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;Gay and Bisexuals&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;TransWomem&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;TransMen&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;Oral Sex&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;Anal Sex&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;Vaginal Sex&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;h2&gt;&lt;br /&gt;&lt;strong&gt;SUPERIOR HIV PROTECTION VS TRUVADA&lt;/strong&gt;&lt;/h2&gt;
&lt;hr /&gt;
&lt;h3&gt;&amp;nbsp;&lt;/h3&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/Apretude%20PrEP%20Injection/Apretude%20Info%20Graphic/7-apretude-men.jpg&quot; width=&quot;500&quot; height=&quot;500&quot; /&gt;&amp;nbsp;&amp;nbsp;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/Apretude%20PrEP%20Injection/Apretude%20Info%20Graphic/9-apretude-men.jpg&quot; width=&quot;500&quot; height=&quot;500&quot; /&gt;&lt;/p&gt;
&lt;h3&gt;&lt;strong&gt;STUDY IN CISGENDER MEN AND TRANSGENDER WOMEN&lt;/strong&gt;&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;&lt;span class=&quot;selection-italic&quot;&gt;&lt;span class=&quot;color-5&quot;&gt;Significantly more people stayed HIV-negative on APRETUDE vs TRUVADA during the study.&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;69% reduction in the risk of acquiring HIV-1 with APRETUDE (0.37/100 person-years) vs TRUVADA (1.22/100 person-years)&lt;/p&gt;
&lt;h2&gt;&lt;img src=&quot;https://apretude.com/content/dam/cf-viiv/apretude-v2/en_US/2-1/Graphic_hiv-infection-line-graph_m.svg&quot; style=&quot;display: block; margin-left: auto; margin-right: auto;&quot; /&gt;&lt;/h2&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;img src=&quot;https://apretude.com/content/dam/cf-viiv/apretude-v2/en_US/2-1/Graphic_hiv-infection-line-graph_dt.svg&quot; style=&quot;display: block; margin-left: auto; margin-right: auto;&quot; /&gt;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;strong&gt;STUDY IN CISGENDER WOMEN&lt;/strong&gt;&lt;/h3&gt;
&lt;div class=&quot;richText component section padding-left-0 padding-right-0 even col-xs-12&quot;&gt;
&lt;div class=&quot;component-content&quot;&gt;
&lt;div class=&quot;richText-content&quot;&gt;&lt;strong&gt;&lt;span class=&quot;selection-italic&quot;&gt;&lt;span class=&quot;color-2&quot;&gt;Significantly more women stayed HIV-negative on APRETUDE vs TRUVADA during the study.&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;span class=&quot;selection-italic&quot;&gt;&lt;span class=&quot;color-2&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;richText-content&quot;&gt;&lt;span class=&quot;selection-italic&quot;&gt;&lt;span class=&quot;color-2&quot;&gt;&lt;span class=&quot;selection-bold&quot;&gt;90% reduction in the risk of acquiring HIV-1 with APRETUDE&lt;/span&gt;&amp;nbsp;(0.15/100 person-years) vs TRUVADA (1.85/100 person-years)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;richText-content&quot;&gt;&amp;nbsp;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;viiv-us-gc-17-image component section mobile-padding-top-3 padding-top-0 odd col-xs-12&quot;&gt;
&lt;div class=&quot;type1 variant1&quot;&gt;
&lt;div id=&quot;image_type1_variant1&quot; class=&quot;authorable-content&quot;&gt;
&lt;div class=&quot;image-wrapper&quot;&gt;
&lt;div class=&quot;image desktop center&quot;&gt;
&lt;div class=&quot;logotype&quot;&gt;&lt;img src=&quot;https://apretude.com/content/dam/cf-viiv/apretude-v2/en_US/2-1/Graphic_hiv-infection-data-line-graph_dt.svg&quot; style=&quot;display: block; margin-left: auto; margin-right: auto;&quot; /&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&lt;strong&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/Apretude%20PrEP%20Injection/Apretude%20Info%20Graphic/4-apretude-men.jpg&quot; width=&quot;650&quot; height=&quot;650&quot; /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;h2&gt;&amp;nbsp;&lt;/h2&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;h3&gt;&lt;strong&gt;Cost of APRETUDE&lt;/strong&gt;&lt;/h3&gt;
&lt;p&gt;In Thailand, VIIV Healthcare has priced APRETUDE, the new injectable PrEP, at 19,500 THB per dose every two months.&lt;/p&gt;
&lt;h3&gt;&amp;nbsp;&lt;/h3&gt;
&lt;h2&gt;&lt;strong&gt;Efficacy of Apretude for all populations&lt;/strong&gt;&lt;/h2&gt;
&lt;hr /&gt;
&lt;p class=&quot;&quot;&gt;Based on the research study&lt;/p&gt;
&lt;table style=&quot;border-collapse: collapse; width: 100%; height: 90px;&quot; border=&quot;1&quot;&gt;
&lt;tbody&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;&amp;nbsp;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot; colspan=&quot;5&quot;&gt;Injectable PrEP Apretude Efficacy in Different Populations&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;&lt;strong&gt;Route or Sex&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;Straight Men&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;Straight Women&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;Gay and Bisexuals&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;TransWomem&lt;/strong&gt;&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;&lt;strong&gt;TransMen&lt;/strong&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;Oral Sex&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;Anal Sex&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style=&quot;height: 18px;&quot;&gt;
&lt;td style=&quot;width: 16.6667%; height: 18px;&quot;&gt;Vaginal Sex&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;td style=&quot;width: 16.6667%; text-align: center; height: 18px;&quot;&gt;more than 99%&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;h3&gt;&amp;nbsp;&lt;/h3&gt;
&lt;p&gt;&lt;strong&gt;Benefits of Injectable PrEP&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;APRETUDE (cabotegravir) offers numerous benefits as a long-acting HIV pre-exposure prophylaxis (PrEP) option:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;High Efficacy&lt;/strong&gt;: Clinical trials show APRETUDE significantly reduces the risk of HIV-1 acquisition compared to daily oral PrEP, with over 99% effectiveness in real-world studies.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Convenience&lt;/strong&gt;: Administered as an injection every two months, APRETUDE removes the need for daily adherence.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Improved Adherence&lt;/strong&gt;: The long-acting nature of APRETUDE helps improve adherence to HIV prevention by removing the burden of daily pills.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Reduction in Stigma and Anxiety&lt;/strong&gt;: Real-world studies indicate APRETUDE reduces stigma and anxiety associated with daily oral PrEP, contributing to better mental health and quality of life.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Diverse Population&lt;/strong&gt;: Clinical trials involved a diverse range of participants, showing APRETUDE&#39;s broad applicability.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Long-Lasting Protection&lt;/strong&gt;: Each injection provides two months of continuous protection, offering reliable and sustained&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&amp;nbsp;&lt;/p&gt;
&lt;p&gt;&lt;a href=&quot;https://www.eu-health.org/booking&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/Booking%20an%20appointment%20at%20PULSE%20CLINIC.png&quot; width=&quot;300&quot; height=&quot;37&quot; style=&quot;display: block; margin-left: auto; margin-right: auto;&quot; /&gt;&lt;/a&gt;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&lt;br /&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;We can help you with your emergency medication needs!&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&lt;strong&gt;Please email us at&amp;nbsp;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;a href=&quot;mailto:info@eu-health.com&quot;&gt;info@eu-health.com&lt;/a&gt;&lt;/span&gt;&amp;nbsp;or chat on your preferred platform.&lt;br /&gt;&lt;/strong&gt;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style=&quot;text-align: center;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;https://wa.me/66994797168&quot;&gt;&lt;/a&gt;&lt;a href=&quot;https://wa.me/66994797168&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/WhatsApp.png&quot; width=&quot;48&quot; height=&quot;82&quot; /&gt;&lt;/a&gt; +66-99-479-7168&amp;nbsp;&lt;/strong&gt;&lt;strong&gt;&lt;a href=&quot;https://line.me/ti/p/~@euwellness&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/line-logo.png&quot; width=&quot;50&quot; height=&quot;85&quot; /&gt;&lt;/a&gt;&amp;nbsp;&lt;a href=&quot;https://line.me/ti/p/~@euwellness&quot;&gt;@euwellness&lt;/a&gt;&amp;nbsp; &amp;nbsp;&amp;nbsp;&lt;/strong&gt;&lt;strong&gt;&lt;a href=&quot;https://api.whatsapp.com/send/?phone=%2B66994797168&amp;amp;text&amp;amp;type=phone_number&amp;amp;app_absent=0&quot;&gt;&lt;img src=&quot;https://cms.pulse-clinic.com/Files/WeChat_App_Icon.png&quot; width=&quot;50&quot; height=&quot;85&quot; /&gt;&lt;/a&gt;&amp;nbsp;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;a href=&quot;https://wa.me/66994797168&quot;&gt;euwellness&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;

People in China travel to Thailand to get Apretude (injectable PrEP) for PrEP